<DOC>
	<DOC>NCT00140023</DOC>
	<brief_summary>The study will assess the clinical efficacy at Day 14-21 (Test of Cure), 14-21 days after starting the study drug; those subjects from whom a baseline pathogen is identified will also be assessed for bacteriologic response. All subjects who receive 1 dose of study medication will be assessed for safety.</brief_summary>
	<brief_title>Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<criteria>Male or female, 18 years age or older, for whom oral, outpatient therapy is indicated. Diagnosis of CAP as manifested by at least 3 or more of the following: cough, pleuritic chest pain, fever (temperature of &gt;37.8 C to &lt;40 C), auscultatory findings on pulmonary examination of rales and/or evidence of pulmonary consolidation, dyspnea, tachypnea, laboratory results of elevated total peripheral white blood count (WBC&gt; 10,000/mm3 or greater than 15% immature neutrophils (bands) Known or suspected hypersensitivity or intolerance to azithromycin or other macrolides. Previously diagnosed disease(s) of immune function, including: subjects with baseline absolute neutrophil count &lt; 1,000/mm3, HIV positive subjects with CD4 count &lt; 200 cells/mm3, any immunoglobin or neutrophil disorder.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>